BIOMAT Database Logo BIOMAT Database Logo

[Action of biologically active compounds on kanamycin inactivation by resistant microorganisms]. 1985

N N Kutsenko, and Z A Kuzina, and L E Alekseeva, and V I Iudelevich, and N I Belousova

Products of kanamycin inactivation were identified chromatographically and radiometrically in E. coli 154, K. aerogenes 600 and P. vulgaris 7470. It was shown that the efficiency of kanamycin inactivation in the membrane fraction was 2 times higher than that in cytosol. A decrease in the culture resistance to kanamycin was observed, when the antibiotic was used in combination with the main proteins or phosphonites: a 16-64-fold decrease in the kanamycin MIC. Comparison of the data on the efficiency of the inactivation inhibition by intact cells and in acellular extracts suggests that the effect of protamine on this process is mediated by the cell membrane, whereas phosphonites can also directly interact with the enzymes inactivating the antibiotic.

UI MeSH Term Description Entries
D007612 Kanamycin Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components. Kanamycin A,Kanamycin Sulfate,Kantrex
D007711 Klebsiella pneumoniae Gram-negative, non-motile, capsulated, gas-producing rods found widely in nature and associated with urinary and respiratory infections in humans. Bacillus pneumoniae,Bacterium pneumoniae crouposae,Hyalococcus pneumoniae,Klebsiella pneumoniae aerogenes,Klebsiella rhinoscleromatis
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009943 Organophosphorus Compounds Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS. Organophosphorus Compound,Organopyrophosphorus Compound,Organopyrophosphorus Compounds,Compound, Organophosphorus,Compound, Organopyrophosphorus,Compounds, Organophosphorus,Compounds, Organopyrophosphorus
D011514 Proteus vulgaris A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that occurs in soil, fecal matter, and sewage. It is an opportunistic pathogen and causes cystitis and pyelonephritis.
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli

Related Publications

N N Kutsenko, and Z A Kuzina, and L E Alekseeva, and V I Iudelevich, and N I Belousova
Biologically Active Antimicrobial Compounds from Marine Microorganisms (2005-2019).
January 2021, Current pharmaceutical biotechnology,
N N Kutsenko, and Z A Kuzina, and L E Alekseeva, and V I Iudelevich, and N I Belousova
Inactivation of biologically active DNA by hydrated electrons.
July 1982, International journal of radiation biology and related studies in physics, chemistry, and medicine,
N N Kutsenko, and Z A Kuzina, and L E Alekseeva, and V I Iudelevich, and N I Belousova
Biologically Active Compounds from Probiotic Microorganisms and Plant Extracts Used as Biopreservatives.
July 2023, Microorganisms,
N N Kutsenko, and Z A Kuzina, and L E Alekseeva, and V I Iudelevich, and N I Belousova
[CONSTITUTION AND ACTION OF BIOLOGICALLY ACTIVE COMPOUNDS. 16. A HYPOTHESIS].
January 1963, Pharmaceutica acta Helvetiae,
N N Kutsenko, and Z A Kuzina, and L E Alekseeva, and V I Iudelevich, and N I Belousova
Inactivation and phosphorylation of kanamycin by drug-resistant Staphylococcus aureus.
September 1968, Applied microbiology,
N N Kutsenko, and Z A Kuzina, and L E Alekseeva, and V I Iudelevich, and N I Belousova
[Theoretical aspects of ascertaining parameters of action of biologically active compounds].
June 1976, Die Pharmazie,
N N Kutsenko, and Z A Kuzina, and L E Alekseeva, and V I Iudelevich, and N I Belousova
[Biologically active iron compounds].
January 1949, Nordisk medicin,
N N Kutsenko, and Z A Kuzina, and L E Alekseeva, and V I Iudelevich, and N I Belousova
[Biologically active silicon compounds].
January 1969, Pure and applied chemistry. Chimie pure et appliquee,
N N Kutsenko, and Z A Kuzina, and L E Alekseeva, and V I Iudelevich, and N I Belousova
[Biologically active compounds produced by microbial endophytes].
January 2014, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
N N Kutsenko, and Z A Kuzina, and L E Alekseeva, and V I Iudelevich, and N I Belousova
Unexplored potential: Biologically active compounds produced by microorganisms from hard-to-reach environments and their applications.
September 2021, Acta biochimica Polonica,
Copied contents to your clipboard!